Bristol-Myers Shares Sink as Lung-Cancer Drug Misses Goal

A cancer drug’s surprise failure in a clinical trial wiped $20 billion off Bristol-Myers Squibb Co.’s market value Friday, and raised questions about one of the industry’s hottest research areas: immunotherapy.

Read more…

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s